Mitochondrial Metabolomics Service — Targeted and Untargeted Profiling of TCA Cycle, Acylcarnitines, and OXPHOS Metabolites

Why Mitochondrial Metabolomics Matters for Drug Toxicity and Metabolic Disease

Mitochondria house the TCA cycle, oxidative phosphorylation (OXPHOS), and fatty acid beta-oxidation. When drugs, toxins, or genetic mutations disrupt these processes, metabolic changes appear first at the organelle level — often before whole-cell or biofluid metabolomics shows detectable shifts. However, whole-cell metabolomics dilutes mitochondrial-specific signals below detection limits, because mitochondria occupy only 10 to 25 percent of cell volume. Our service combines mitochondrial isolation with targeted LC-MS/MS, untargeted LC-HRMS, and GC-MS profiling to deliver organelle-resolved metabolic data for drug toxicity assessment, metabolic disease research, and cancer metabolism studies.

Targeted mitochondrial metabolomics by LC-MS/MS and GC-MS enables you to:

• Quantify TCA cycle intermediates — citrate, isocitrate, alpha-ketoglutarate, succinate, fumarate, malate, and oxaloacetate — as individual metabolites, not a summed pool, to identify enzymatic bottleneck points
• Profile acylcarnitines — from acetylcarnitine (C2) to palmitoylcarnitine (C16) and stearoylcarnitine (C18) — as direct readouts of CPT1/CPT2 activity and mitochondrial fatty acid oxidation flux
• Measure redox metabolites — NAD+, NADH, NADP+, NADPH, FAD, and reduced glutathione — to assess electron transport chain function and oxidative stress at the metabolite level
• Detect drug-induced mitochondrial toxicity — citrate accumulation, acylcarnitine depletion, and NAD+/NADH ratio shifts are early biomarkers of complex I inhibition, beta-oxidation blockade, and OXPHOS uncoupling

Mitochondrial Metabolomics Challenges — Organelle Resolution vs Whole-Cell Averaging

Most metabolomics services profile whole-cell or whole-tissue extracts — which averages mitochondrial signals with the far more abundant cytoplasmic pool. If a drug inhibits complex I and acylcarnitines accumulate inside mitochondria, this signal is diluted below significance in a whole-cell extract, making acylcarnitine profiling unreliable without mitochondrial isolation. Creative Proteomics resolves this with a mitochondrial isolation-first approach combined with targeted LC-MS/MS panels:

• Organelle-resolved, not whole-cell averaged: We isolate mitochondria from tissue or cells using differential centrifugation with density gradient purification, then extract metabolites directly from the mitochondrial pellet. This enriches mitochondrial-specific metabolites 5 to 20 fold compared to whole-cell extracts, depending on the analyte.
• Four complementary panels from one isolation: Your mitochondrial sample is split into four targeted LC-MS/MS and GC-MS panels — TCA cycle, acylcarnitine/carnitine, OXPHOS and redox, and mitochondrial lipids — providing comprehensive organelle-level coverage without duplicate sample submissions.
• Drug toxicity biomarker focus: Our panels are designed around the metabolite shifts most commonly reported in drug-induced mitochondrial toxicity studies — citrate accumulation (TCA cycle bottleneck), acylcarnitine depletion (CPT1 inhibition), NAD+/NADH ratio collapse (complex I inhibition), and cardiolipin remodeling (membrane damage).

Mitochondrial Metabolite Detection Panels

Our mitochondrial metabolomics service offers four complementary panels — deployable independently or together from a single mitochondrial isolation. Each panel includes class-specific isotopically labeled internal standards and per-analyte multi-point calibration for TCA cycle metabolite analysis, acylcarnitine profiling, OXPHOS metabolite quantification, and mitochondrial lipid characterization.

Panel 1: TCA Cycle Intermediates (LC-MS/MS)

Panel 2: Acylcarnitine and Carnitine Profile (LC-MS/MS)

Custom panels: add specific acylcarnitine species (e.g., C5-OH, C3-DC, C4-DC, C5-DC, C12-DC, C14-DC, C16-OH, C18-OH), integrate with fatty acid metabolism profiling, or combine with metabolic flux analysis using 13C-labeled substrates. Contact us with your target list during study design.

Panel 3: OXPHOS and Redox Metabolites (LC-MS/MS)

Panel 4: Mitochondrial Lipid Signaling (LC-MS/MS)

Targeted vs Untargeted Mitochondrial Profiling — Which Approach Fits Your Study?

Researchers have two primary approaches for mitochondrial metabolomics — but they answer different questions. The table below clarifies which approach fits your research goal.

Not sure which approach fits your study? Most drug toxicity projects benefit from the targeted panels first (mechanism, biomarkers) followed by untargeted discovery to identify unexpected metabolic perturbations. Contact us during study design and we will recommend the optimal configuration for your sample type and research question.

Why Choose Our Mitochondrial Metabolomics Service?

• Mitochondrial Isolation, Not Whole-Cell Averaging
  We isolate mitochondria from your tissue or cell samples using differential centrifugation with density gradient purification before metabolite extraction. This enriches mitochondrial-specific metabolites 5 to 20 fold compared to whole-cell extracts, providing organelle-level resolution that whole-cell metabolomics cannot achieve.
• Four Complementary Panels from One Isolation
  Your mitochondrial sample is split into four LC-MS/MS and GC-MS panels — TCA cycle, acylcarnitine/carnitine, OXPHOS and redox, and mitochondrial lipids. Comprehensive organelle-level coverage without duplicate sample submissions.
• Drug Toxicity Biomarker Focus
  Our panels are designed around the metabolite shifts most commonly reported in drug-induced mitochondrial toxicity: citrate accumulation (TCA bottleneck), acylcarnitine depletion (CPT1 inhibition by malonyl-CoA), NAD+/NADH ratio collapse (Complex I inhibition), and cardiolipin remodeling (membrane damage). Every analyte maps to a specific mechanistic readout.
• Per-Analyte Calibration with Isotopically Labeled Standards
  Every analyte is quantified against its own multi-point calibration curve with class-matched isotopically labeled internal standards. Your citrate data is calibrated against a citrate standard curve — not estimated from a surrogate. Acylcarnitines are quantified with deuterated C2, C3, C8, and C16 internal standards.
• Professional Deliverables for Collaborators and Reviewers
  Quantitative tables with per-analyte concentrations and QC flags, calibration and QC reports, extracted ion chromatograms with peak assignments, raw data files, and a methods appendix formatted for direct inclusion in your manuscript.

Mitochondrial Metabolomics Instrumentation and LC-MS/MS Method Performance

Our mitochondrial metabolomics platform integrates LC-MS/MS for polar metabolites — TCA cycle intermediates, acylcarnitines, OXPHOS metabolites, and redox cofactors — with GC-MS for organic acids and fatty acid derivatives. All instruments are configured for high-sensitivity quantification from low microgram mitochondrial protein inputs.

Internal Standards and Calibration Strategy

• TCA cycle panel: 13C6-citrate, 13C4-succinate, 13C4-fumarate, 13C4-malate, and D5-alpha-ketoglutarate as isotopically labeled internal standards spiked at extraction; 6 to 8 point calibration curves per analyte in surrogate matrix.
• Acylcarnitine panel: D3-acetylcarnitine (C2), D3-propionylcarnitine (C3), D3-octanoylcarnitine (C8), D3-palmitoylcarnitine (C16), and D3-carnitine (C0) as deuterated internal standards spiked at extraction; per-analyte calibration in methanol-water matrix.
• OXPHOS and redox panel: 13C5-NAD+, 13C5-NADH, 13C5-ATP, and 13C5-ADP as isotopically labeled internal standards; NAD+/NADH ratio reported per sample with method-specific extraction to minimize interconversion.
• QC Monitoring: Pooled QC every 8 injections; mitochondrial purity marker (citrate synthase activity) reported per isolation batch; Westgard multi-rule evaluation; LOESS signal drift correction; flagged analytes (RSD greater than 30%) reported.

Mitochondrial Metabolomics Workflow — From Isolation to Quantification

Mitochondrial Metabolomics Sample Collection and Isolation Guidelines

Proper sample handling is critical for mitochondrial metabolomics — mitochondrial metabolites are labile and mitochondrial membrane potential must be preserved during isolation. The following guidelines ensure metabolic integrity from collection through analysis.

Critical Notes:

• Oxaloacetate and pyruvate are extremely labile — oxaloacetate spontaneously decarboxylates to pyruvate at physiological pH. Samples must be quenched and extracted at low temperature (4 degrees C or below) with acidic conditions to preserve oxaloacetate. If oxaloacetate is critical to your study, discuss specialized quenching protocols during study design.
• NAD+ and NADH interconvert rapidly — acid-base extraction methods are required to separate NAD+ (acid-stable) from NADH (base-stable). We use a dual-extraction approach: acid extraction for NAD+ and base extraction for NADH from parallel aliquots. Do not freeze-thaw samples before NAD extraction.
• Acylcarnitines in plasma reflect whole-body mitochondrial FAO status — for tissue-specific drug toxicity studies, mitochondrial isolation from the target organ is strongly recommended. Energy metabolism profiling from plasma alone may miss organ-specific dysfunction.
• Mitochondrial purity matters — cytosolic contamination (lactate dehydrogenase activity greater than 5 percent of total) dilutes mitochondrial-specific signals. We report purity metrics for every isolation batch and flag samples below threshold.

Mitochondrial Metabolomics Data Deliverables and Reporting

Our mitochondrial metabolomics deliverables are designed for direct integration into drug toxicity studies, manuscript preparation, and regulatory submissions. Every data package includes per-analyte absolute quantification, QC documentation, and raw data files for independent verification.

Applications of Mitochondrial Metabolomics

Our mitochondrial metabolomics service supports researchers across disciplines where organelle-level metabolic data drives decisions:

• Drug-Induced Mitochondrial Toxicity — Screen compounds for Complex I to V inhibition, CPT1 blockade, and OXPHOS uncoupling using TCA cycle, acylcarnitine, and redox metabolite shifts as mechanistic biomarkers
• Metabolic Disease Research — Profile mitochondrial dysfunction in diabetes, NAFLD, obesity, and inborn errors of metabolism using TCA intermediate quantification and acylcarnitine panels
• Cancer Metabolism — Quantify oncometabolites (succinate, fumarate, 2-hydroxyglutarate), assess TCA cycle rewiring, OXPHOS metabolite shifts, and mitochondrial lipid remodeling in tumor samples
• Neurodegeneration and Aging — Measure NAD+/NADH decline, CoQ10 depletion, and cardiolipin remodeling in brain tissue mitochondria for Alzheimer, Parkinson, and aging studies
• Clinical Biomarker Discovery — Validate plasma acylcarnitine panels as non-invasive biomarkers of mitochondrial FAO disorders and drug toxicity in cohort-scale studies

Case Study: Volatile Anesthetic-Induced Mitochondrial TCA Cycle Disruption in Neonatal Mice

Mechanisms underlying neonate-specific metabolic effects of volatile anesthetics

Stokes, J., Freed, A., Bornstein, R., Su, K. N., Snell, J., Pan, A., Sun, G. X., Park, K. Y., Jung, S., Worstman, H., Johnson, B. M., Morgan, P. G., Sedensky, M. M., and Johnson, S. C. | eLife, 2021, 10, e65400

DOI: 10.7554/eLife.65400

---

Background

Volatile anesthetics (isoflurane, sevoflurane, halothane) are known to interfere with mitochondrial electron transport chain function, but the specific metabolic consequences — particularly in neonates — were poorly understood. Neonatal mice exposed to isoflurane experience acute depletion of beta-hydroxybutyrate (beta-HB), the primary ketone body fueling the neonatal brain, but the mechanism was unknown.

Challenge: Identify the mitochondrial metabolic pathway by which volatile anesthetics disrupt ketone body production in neonatal mice, using targeted metabolomics of TCA cycle intermediates and acylcarnitines to pinpoint the enzymatic bottleneck.

---

Key Findings

---

What This Means for Your Drug Toxicity Research

• Citrate accumulation is an early biomarker of TCA cycle disruption. The 100 percent increase in liver citrate within 30 minutes of anesthetic exposure occurred before any clinical phenotype was visible. Our TCA cycle panel detects this shift at the organelle level — in isolated mitochondria — with absolute quantification.
• Acylcarnitine depletion confirms CPT1 inhibition without enzyme assays. The broadly reduced acylcarnitine profile directly demonstrates that fatty acid oxidation was blocked at the CPT1 step. Our acylcarnitine panel provides this readout from a single mitochondrial extraction.
• The TCA cycle to ACC to malonyl-CoA to CPT1 axis is a single connected pathway. Drug-induced mitochondrial toxicity often cascades through multiple metabolite classes simultaneously. Our four-panel approach captures all shifts in one isolation — citrate (TCA panel), acylcarnitines (acylcarnitine panel), and NAD+/NADH (redox panel) — providing a comprehensive mechanistic profile of mitochondrial dysfunction.
• Sub-anesthetic doses can cause maximum metabolic disruption. The 0.2 percent isoflurane dose — below the minimum on a clinical vaporizer — caused equal or greater beta-HB depletion than the full anesthetic dose. This means mitochondrial metabolomics can detect toxicity at doses that do not produce visible phenotypic effects.

---

Conclusion

This study demonstrates that targeted mitochondrial metabolomics — profiling TCA cycle intermediates and acylcarnitines from tissue samples — can identify the exact enzymatic bottleneck in drug-induced metabolic disruption. Our mitochondrial metabolomics service delivers the same quantitative rigor: per-analyte concentrations by LC-MS/MS with isotopically labeled internal standards, from isolated mitochondria, with mechanistic biomarker readouts for drug toxicity assessment.